Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,069,894
  • Shares Outstanding, K 43,885
  • Annual Sales, $ 1,449 M
  • Annual Income, $ -104,500 K
  • 60-Month Beta 0.78
  • Price/Sales 2.83
  • Price/Cash Flow N/A
  • Price/Book 1.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 2.43
  • Number of Estimates 4
  • High Estimate 2.65
  • Low Estimate 2.04
  • Prior Year -11.32
  • Growth Rate Est. (year over year) +121.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.58 +26.70%
on 03/18/20
100.99 -5.18%
on 03/10/20
-2.50 (-2.54%)
since 03/06/20
3-Month
75.58 +26.70%
on 03/18/20
116.98 -18.14%
on 02/24/20
+9.19 (+10.62%)
since 01/06/20
52-Week
74.31 +28.87%
on 07/23/19
118.66 -19.30%
on 04/08/19
-25.05 (-20.74%)
since 04/05/19

Most Recent Stories

More News
United Therapeutics (UTHR) Stock Moves -0.98%: What You Should Know

In the latest trading session, United Therapeutics (UTHR) closed at $93.90, marking a -0.98% move from the previous day.

UTHR : 95.76 (+3.26%)
United Therapeutics (UTHR) Down 8.7% Since Last Earnings Report: Can It Rebound?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR : 95.76 (+3.26%)
Is United Therapeutics (UTHR) Outperforming Other Medical Stocks This Year?

Is (UTHR) Outperforming Other Medical Stocks This Year?

UTHR : 95.76 (+3.26%)
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

AZN : 44.31 (+0.80%)
SPPI : 2.36 (+10.28%)
UTHR : 95.76 (+3.26%)
PCRX : 32.00 (+3.90%)
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health

Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health

CAH : 49.35 (+5.88%)
MCK : 135.20 (+7.74%)
UTHR : 95.76 (+3.26%)
VRTU : 27.20 (+17.60%)
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

United Therapeutics (UTHR) misses fourth-quarter estimates on both fronts. Stock declines in response.

MDT : 94.09 (+9.06%)
LLY : 141.61 (+1.40%)
UTHR : 95.76 (+3.26%)
NVS : 85.73 (+2.50%)
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the fourth quarter of 2019 while revenues beat estimates.

UTHR : 95.76 (+3.26%)
CLVS : 6.80 (+11.48%)
4 Finest Value Stocks Based on Discounted PEG

A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.

CAH : 49.35 (+5.88%)
MCK : 135.20 (+7.74%)
UTHR : 95.76 (+3.26%)
VRTU : 27.20 (+17.60%)
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates

Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.

UTHR : 95.76 (+3.26%)
JAZZ : 105.77 (+7.10%)
USNA : 70.12 (+12.41%)
SLNO : 2.19 (-2.23%)
United Therapeutics (UTHR) Lags Q4 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -51.42% and -11.10%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...

UTHR : 95.76 (+3.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade UTHR with:

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

2nd Resistance Point 98.21
1st Resistance Point 96.98
Last Price 95.76
1st Support Level 93.91
2nd Support Level 92.07

See More

52-Week High 118.66
Fibonacci 61.8% 101.72
Fibonacci 50% 96.49
Last Price 95.76
Fibonacci 38.2% 91.25
52-Week Low 74.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar